Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 59-63, February 2003

Uracil/tegafur plus oral leucovorin does not affect survival rates but may be better tolerated than standard fluorouracil and leucovorin for previously untreated metastatic colorectal cancer:☆☆☆★

Abstracted from: Douillard J, Hoff P, Skillings J et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2002; 20: 3605–16.

Department of Gastroenterology, University Medical Center Ljubljana, Slovenia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Taiho Pharmaceutical Company, Japan; Bristol-Myers Squibb, New Jersey.

☆☆ For correspondence: Professor Douillard, Centre Rene Gauducheau, Site Hospitalier Nord, France. E-mail: jy-douillard@nantes.fnclcc.fr.

★ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(02)00125-1

doi:10.1016/S0305-7372(02)00125-1

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 59-63, February 2003

Article Tools